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Arsenic trioxide suppresses tumour growth in squamous cell lung carcinoma 
LL Leung, SK Lam, JCM Ho
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong
introduction: Squamous cell lung carcinoma (SCC) belongs to the second most common subtype in non–small-
cell lung carcinoma. Recently, doublet chemotherapy regimens remain the cornerstone of first-line systemic 
treatment. Therefore, new therapeutic approach is urgently needed. Arsenic trioxide (ATO) is a traditional 
Chinese medicine which has multiple anti-cancer mechanisms including apoptosis. ATO has been used 
clinically in acute promyelocytic leukaemia. ATO has been shown to induce apoptosis in lung adenocarcinoma 
in vitro and in vivo. The aim of this study was to determine the anti-cancer effect of ATO in SCC. 
Methods: Two SCC cell lines were obtained: SK-MES-1 and SW900. Cell cycle arrest, phosphatidylserine 
externalisation, mitochondrial membrane depolarisation, and reactive oxidative species level were analysed 
by flow cytometry. Cell viability and protein expression were determined by MTT assay and Western blot, 
respectively. Effect of ATO was demonstrated by SK-MES-1 xenograft model in vivo.
Results: Upon ATO treatment, G2/M arrest was noted in both cell lines while level of phosphatidylserine 
externalisation and mitochondrial membrane depolarisation were increased in SK-MES-1 cells only. Hydrogen 
peroxide was raised in SK-MES-1 cells while decreased in SW900 cells. Superoxide level was decreased in 
SK-MES-1 cells while unaltered in SW900 cells. Sustained Erk activation was observed in SK-MES-1 cells 
only. The expression level of p-p38 was increased in SK-MES-1 cells while it was decreased in SW900 cells. 
Cleaved caspase 3 was elevated in both cell lines. Cleaved PARP was increased in SK-MES-1 cells while Bak 
was upregulated in SW900 cells. Anti-apoptotic protein XIAP was decreased in both cell lines, while Bcl-2 was 
downregulated in SK-MES-1 cells only. Transcriptional factor protein, E2F-1, was decreased in both cell lines, 
while RRM1 and thymidylate synthase were decreased in SK-MES-1 cells only. ATO (7.5 mg/kg) decreased the 
tumour size in SK-MES-1 xenograft in vivo.
Conclusion: ATO induced apoptotic and anti-proliferative effects in SCC in vitro and in vivo.
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Defining criteria for rheumatoid arthritis patient-derived Disease Activity Score (PDAS) that 
correspond to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI) Based 
Disease Statuses And Response Criteria
MH Leung1, D Farewell2, E Choy2, CS Lau1
1 Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
2 Section of Rheumatology, Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
introduction: Patient-derived Disease Activity Score with ESR (PDAS1) and without ESR (PDAS2) in rheumatoid 
arthritis (RA) are validated patient-reported outcome measures of disease activity and correlate highly with 
Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI). The purpose of this study was to 
develop and examine their performance of status and responder criteria.
Method: Data from 299 RA patients (originally used to develop PDAS) were analysed using receiver operator 
characteristic (ROC) curves to determine optimal cut-points for PDAS corresponding to DAS28 and CDAI 
criteria for remission, low-, medium- and high-disease activities. Data from 56 RA patients started on disease-
modifying drugs before and 6 months after treatment were used to determine PDAS thresholds corresponding 
to the European League Against Rheumatism (EULAR) good or moderate responses. Agreement was assessed 
with Kappa statistics.
Results: Key cut-points for PDAS1&2 were 3.5, 4.5, 4.8, and 3.8, 4.6, 5.0 respectively. Area under ROC curves 
ranged from 0.89 to 0.95. Sensitivities ranged from 79% to 99%, and specificities from 61% to 89%. Moderate-
to-good agreement with DAS28 categories was observed: respectively, k=0.44 and 0.31 for PDAS1&2. 
Corresponding agreements with CDAI were k=0.3 and 0.4. Crucially, these agreements were comparable to 
those of CDAI and DAS28 (k=0.54). The criteria that corresponded to EULAR moderate and good response 
were 0.4, 0.8 for PDAS1 and 0.3, 1.2 for PDAS2. Area under the ROC curve ranged from 0.88 to 0.93. Sensitivities 
ranged from 72% to 100% and specificities from 77% to 94%. Agreement of DAS28 response with PDAS1&2 were 
k=0.46 and 0.38 respectively. Again, these were comparable to the agreement between DAS28 and CDAI in this 
patient group (k=0.55).
Conclusion: Disease activity and treatment response for PDAS1&2 have comparable agreement to standard 
criteria DAS28 and CDAI. PDAS has potential use in routine practice and research.
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